nilotinib

Known as: 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide, Nilotinibum 
An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients compares nilotinib and imatinib in patients… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
In BCR-ABL-positive chronic myeloid leu-kemia (CML), the tyrosine kinase inhibitor (TKI) imatinib acts as an antileukemic agent… (More)
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Nilotinib has a higher binding affinity and selectivity for BCR-ABL with respect to imatinib and is an effective treatment of… (More)
  • table 1
  • table 2
  • table 4
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Chronic myeloid leukemia (CML) stem and progenitor cells overexpress BcrAbl and are insensitive to imatinib mesylate (IM). We… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have… (More)
  • table 1
  • figure 1
  • table 4
  • table 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Intrinsic sensitivity of newly diagnosed chronic myeloid leukemia (CML) patients to imatinib (IC50(imatinib)) correlates with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?